Delcath Systems Balances Growth with Rising Costs

Delcath Systems, Inc. ((DCTH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Delcath Systems’ latest earnings call delivered a cautiously optimistic tone, as management balanced strong commercial momentum with clear operational challenges. Record new patient starts, robust revenue growth, and encouraging CHOPIN data underscored the opportunity, while slower site activations, rising costs, and European reimbursement hurdles kept expectations in check.

Top-Line Revenue Growth

Delcath posted Q1 2026 revenue of $25.0 million, up about 26% from $19.8 million a year earlier, signaling solid demand for its liver-directed therapies. HEPZATO KIT accounted for $23.3 million and CHEMOSAT for $1.7 million, confirming that the core franchise is driving the bulk of the company’s growth.

Volume Momentum and New Patient Starts

The company reported record new patient starts in the quarter, with roughly 0.7 new patients per site per month, matching or slightly exceeding last year’s pace. Management cited 36% year-over-year volume growth and mid‑20% quarter‑over‑quarter growth versus Q4 2025, pointing to accelerating utilization of its platform.

Commercial Footprint Expansion

Delcath has nearly completed its U.S. commercial expansion into nine regions, while fully deploying a larger, trained MSL team to support physicians. The company now counts 29 REMS‑certified sites and is actively engaging with over 50 potential centers, including 38 where staff have participated in precepting.

CHOPIN Clinical Evidence Driving Adoption

Results from the CHOPIN study, published in Lancet Oncology, showed response rates rising from about 40% with HEPZATO alone to roughly 76% when combined with immunotherapy. Management noted early anecdotal adoption and said CHOPIN is already influencing treatment patterns at several centers, reinforcing the therapy’s perceived value.

Clinical Program Progress

In metastatic colorectal cancer, Delcath has 13 sites active for screening and plans to bring nearly all 26 targeted trial sites online by the end of 2026, with interim data expected in late 2027. The metastatic breast cancer program has four sites ready to screen and aims for 15 active sites by late 2026, expanding the company’s longer‑term pipeline.

Cash Position and Balance Sheet

The company ended Q1 with $89.3 million in cash and investments and reported no debt, underscoring a solid liquidity cushion. Operations generated $0.9 million of cash, and Delcath repurchased about 300,000 shares for roughly $3 million in the quarter, bringing total buybacks to $9 million under its $25 million program.

Operational Initiatives to Mitigate Seasonality

To address capacity bottlenecks and seasonal slowdowns, management is incentivizing centers to train second treatment teams, reducing dependence on single specialized groups. The company is also building referral networks and multi‑source patient identification strategies to keep case flow more consistent throughout the year.

Slower Site Activation Pace

Despite commercial momentum, Delcath trimmed its target for year‑end active centers to 37, reflecting slower‑than‑expected openings and limited near‑term visibility. The company now expects to reach about 40 active treatment centers by Q1 2027, suggesting a more measured ramp in its U.S. footprint.

Sluggish Clinical Enrollment in mCRC

Enrollment in the metastatic colorectal cancer trial is lagging, with only seven patients enrolled despite 13 sites open for screening. Management acknowledged the slower‑than‑planned pace, highlighting execution risk around timelines for generating pivotal clinical data.

Profitability Decline and Net Loss

Profitability softened in Q1, with a net loss of $1.1 million versus net income of $1.1 million in the prior‑year period, a swing of about $2.2 million. Adjusted EBITDA fell to $3.4 million from $7.6 million a year ago, a roughly 55% decline, reflecting higher operating investment despite revenue growth.

Rising R&D and SG&A Spending

R&D expense nearly doubled to $9.8 million from $5.0 million, as the company invests heavily in its colorectal and breast cancer programs, and full‑year R&D is now expected to be about 70%–75% higher than 2025. SG&A rose to $13.1 million from $11.3 million and is projected to climb roughly 60% in 2026, mirroring the expanding commercial infrastructure.

Gross Margin Slightly Lower

Gross margin remained strong at 85% in Q1, only slightly below the 86% reported a year earlier, showing the high‑margin profile of Delcath’s product portfolio. The modest decline suggests that while scaling and investments are ongoing, the underlying economics of the business remain attractive.

European Reimbursement Headwinds

Growth in Europe continues to be constrained by reimbursement hurdles and conservative practice patterns, limiting the region’s contribution. Management currently anticipates only modest single‑digit growth in Europe in 2026 unless reimbursement improves in key markets, placing more pressure on U.S. execution.

Seasonality and Capacity Risks

The company highlighted seasonal scheduling challenges and the reliance on single trained treatment teams at many sites, which can weigh on volumes in the second half of the year. Patient preferences around timing of therapy further complicate throughput, reinforcing the importance of the company’s capacity and referral initiatives.

Real-World Breast Cancer Data Limitations

Real‑world data presented at ESMO in breast cancer showed heavily pretreated patients receiving a median of only one cycle, even though protocols call for two, and about 8% Grade 3/4 adverse events. Management framed these findings as indicative of both the limits of current real‑world evidence and the variability in outcomes in late‑line settings.

Guidance and Profitability Outlook

Delcath reaffirmed its forecast for at least $100 million in 2026 revenue, driven by an expected 20% increase in HEPZATO kit volume versus 2025 and supported by gross margins of 85%–87%. The company expects to generate positive adjusted EBITDA for the rest of the year, even as R&D is set to rise 70%–75% and SG&A about 60%, with guidance assuming similar seasonality to 2025 and a tempered site activation plan.

Delcath’s earnings call painted the picture of a company in scaling mode, leveraging strong demand and compelling clinical evidence while managing higher costs and operational friction. For investors, the story hinges on whether management can convert current momentum into sustained growth, hit its $100 million revenue target, and return to stronger profitability amid lingering execution risks.